Oric Pharmaceuticals, Inc. 4

Richard A. Heyman sold 300 shares of Oric Pharmaceuticals, Inc. common stock at about $12.00 per share under a Rule 10b5-1 plan.

On July 6, 2026, Richard A. Heyman, a director-level insider of Oric Pharmaceuticals, Inc., effected a small open-market sale of 300 shares of common stock at approximately $12.00 per share under a pre-arranged Rule 10b5-1 trading plan through RAHD Capital, LLC, over which he has voting and investment control. The transaction totaled about $3,600 in value and was reported as an indirect disposition, reducing the indirect holdings associated with RAHD Capital while leaving the reporting person with 41,800 shares of common stock held directly after the trade. The sale appears routine and modest in size relative to typical insider liquidity events and does not materially alter the insider’s overall ownership stake.

Filing Facts

CIK

1796280

Ticker

ORIC

Form

4

Source Type

fda

Accession

0001584759-26-000012

Alert Tier

5